Evolving Strategies for Leveraging SGLT2 Inhibitor Therapy in Type 2 Diabetes

Get patient-specific guidance on T2D treatment options and insights on managing CVD and CKD risk.

Share

Program Content

Activities

How I Use SGLT2 Inhibitors
How I Use SGLT2 Inhibitors in T2D for Cardiovascular and Renal Disease
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 10, 2020

Expires: November 09, 2021

Activities

SGLT2 Inhibitor Therapy
Slides on SGLT2 Inhibitor Therapy in Type 2 Diabetes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Activities

Diabetes Consult
Diabetes Consult: Selecting T2D Treatments for High-Risk Patients
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: April 12, 2023

No activities added yet

Faculty

cover img faculity

Martin J. Abrahamson, MD, FACP

Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Department of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

cover img faculity

Zachary T. Bloomgarden, MD, MACE

Clinical Professor
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

cover img faculity

Anne Peters, MD

Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

cover img faculity

Anne Peters, MD

Director
USC Clinical Diabetes Programs
Professor of Clinical Medicine
Keck School of Medicine of USC
University of Southern California
Los Angeles, California

cover img faculity

Richard E. Pratley, MD

AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, Advent Health Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins School of Medicine
Orlando, Florida

cover img faculity

Robert S. Zimmerman, MD

Vice Chairman
Director, Cleveland Clinic Diabetes Center
Department of Endocrinology
Cleveland Clinic
Cleveland, Ohio

Provided by

ProCE Banner

Supporters

This activity is supported by an independent educational grant from

Boehringer Ingelheim